Notable
Multiple-Ascending-Dose Study of XTMAB-16 · Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Primary endpoint(s) modified
Also in this update: Enrollment reduced: 94 → 32 participants; Primary and study completion moved earlier from May 2029 to Oct 31, 2026
Xentria, Inc.Phase 1/2 NCT05890729 Registry history of NCT05890729 on ClinicalTrials.gov (opens the registry)
Updated